GH Research (NASDAQ:GHRS) Sees Strong Trading Volume - Should You Buy?

Key Points

• GH Research shares rose 2.1% to $30.38 amid trading volume that was 52% above the prior session, with roughly 469,567 shares changing hands.
• Analyst sentiment is generally positive: ten analysts rate the stock Buy versus two Sell ratings, producing a “Moderate Buy” consensus and an average price target of $45.00. Recent targets range from $39 to $44, although some firms maintain bearish views.
• GH Research remains a pre-profit clinical-stage biotechnology company, with analysts expecting a $1.33-per-share loss this year. Its valuation depends heavily on future clinical and commercial progress, despite forecasts for narrowing losses over the long term.

Shares of GH Research PLC (NASDAQ:GHRS - Get Free Report) saw strong trading volume on Wednesday . Approximately 469,567 shares changed hands during mid-day trading, an increase of 52% from the previous session's volume of 308,722 shares.The stock last traded at $30.38 and had previously closed at $29.08.

Key Stories Impacting GH Research

Here are the key news stories impacting GH Research this week:

• Positive Sentiment: HC Wainwright raised its earnings forecasts for GH Research across several periods, including FY2026 EPS to ($1.14) from ($1.21) and FY2027 EPS to ($1.62) from ($1.64). The firm also modestly improved estimates for the second, third and fourth quarters of 2027. These revisions indicate expectations for somewhat narrower losses and reinforce HC Wainwright’s Buy rating.
• Positive Sentiment: The analyst’s long-term estimates project improving results by FY2030, when the expected loss narrows to ($1.22) per share from projected losses of ($1.76) in FY2028 and ($2.11) in FY2029. While GH Research remains pre-profit, the trajectory may support bullish sentiment among investors focused on the company’s longer-term development prospects.
• Neutral Sentiment: Reported short interest was zero shares as of August 11, unchanged from the prior reporting date. This provides no evidence of meaningful short-covering activity or a short-squeeze catalyst behind the recent strength.
• Negative Sentiment: GH Research is still expected to post losses in every forecast period provided, including a consensus loss of ($1.33) per share for the current year. The company’s valuation and stock performance therefore remain highly dependent on future clinical and commercial progress rather than near-term earnings.

Wall Street Analyst Weigh In

A number of research firms recently commented on GHRS. Wells Fargo & Company started coverage on GH Research in a research report on Monday, July 27th. They set an "overweight" rating and a $44.00 price target on the stock. Zacks Research downgraded GH Research from a "hold" rating to a "strong sell" rating in a research report on Wednesday, July 15th. Weiss Ratings reissued a "sell (d-)" rating on shares of GH Research in a research note on Friday, July 17th. Needham & Company LLC increased their target price on GH Research from $32.00 to $39.00 and gave the stock a "buy" rating in a report on Thursday, August 6th. Finally, Guggenheim raised their target price on GH Research from $34.00 to $40.00 and gave the company a "buy" rating in a research note on Friday, August 7th. Ten research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $45.00.

GH Research Stock Up 2.1%

The stock's 50-day moving average price is $25.88 and its 200-day moving average price is $20.37. The company has a market capitalization of $2.04 billion, a price-to-earnings ratio of -29.68 and a beta of 1.29.

GH Research (NASDAQ:GHRS - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.23) earnings per share for the quarter, beating analysts' consensus estimates of ($0.29) by $0.06. On average, equities research analysts anticipate that GH Research PLC will post -1.33 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Royal Bank of Canada raised its position in shares of GH Research by 43.1% during the first quarter. Royal Bank of Canada now owns 2,590 shares of the company's stock worth $36,000 after acquiring an additional 780 shares during the last quarter. Troluce Capital Advisors LLC boosted its holdings in GH Research by 165.4% in the first quarter. Troluce Capital Advisors LLC now owns 990,472 shares of the company's stock valued at $13,926,000 after acquiring an additional 617,260 shares during the last quarter. Renaissance Technologies LLC bought a new position in GH Research in the first quarter valued at about $290,000. North Star Investment Management Corp. acquired a new stake in GH Research in the first quarter worth about $31,000. Finally, Avoro Capital Advisors LLC acquired a new stake in GH Research in the fourth quarter worth about $22,860,000. 56.90% of the stock is currently owned by institutional investors.

About GH Research

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm's lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source